Imunon, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMNN Nasdaq 2836 imunon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Imunon, Inc.

IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer - Oct 1st, 2026 9:40 am
IMUNON Converts $1.2 Million of Debt-to-Equity - Sep 29th, 2026 6:00 am
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan - Sep 24th, 2026 6:05 am
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review - Sep 22nd, 2026 6:05 am
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 - Sep 10th, 2026 7:30 am
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress - Sep 9th, 2026 6:30 am
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 - Aug 26th, 2026 6:30 am
IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial - Aug 19th, 2026 6:10 am
Imunon (IMNN) Q2 2026 Earnings Call Transcript - Aug 11th, 2026 8:12 pm
Imunon, Inc. Q2 2026 Earnings Call Summary - Aug 11th, 2026 10:52 am
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 11th, 2026 6:00 am
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 - Aug 4th, 2026 6:00 am
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer - Jul 30th, 2026 7:00 am
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Jul 30th, 2026 6:30 am
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development - Jul 23rd, 2026 7:25 am
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer - Jul 21st, 2026 7:00 am
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients - Jul 21st, 2026 6:30 am
OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD - Jul 9th, 2026 10:02 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am